Prognostic value of myocardial fibrosis in severe aortic stenosis: study protocol for a prospective observational multi-center study (FIB-AS)

Abstract

Background: Adverse cardiac remodeling with a myocardial fibrosis as a key pathophysiologic component may be associated to worse survival in aortic stenosis (AS) patients. Therefore, with the application of advanced cardiac imaging we aim to investigate left ventricular myocardial fibrosis in severe AS patients undergoing aortic valve replacement (AVR) and determine its impact with post-intervention clinical outcomes. Methods: In a prospective, observational, cohort study patients with severe AS scheduled either for surgical or transcatheter AVR will be recruited from two tertiary heart centers in Denmark and Lithuania. All patients will receive standard of care in accordance with the current guidelines and will undergo additional imaging testing before and after AVR: echocardiography with deformation analysis and cardiovascular magnetic resonance (CMR) with T1 parametric mapping. Those undergoing surgical AVR will also have a myocardial biopsy sampled at the time of a surgery for histological validation. Patients will be recruited over a 2-year period and followed up to 2 years to ascertain clinical outcomes. Follow-up CMR will be performed 12 months following AVR, and echocardiography with deformation analysis will be performed 3, 12, and 24 months following AVR. The study primary outcome is a composite of all-cause mortality and major adverse cardiovascular events. Discussion: Despite continuous effort of research community there is still a lack of early predictors of left ventricular decompensation in AS, which could improve patient risk stratification and guide the optimal timing for aortic valve intervention, before irreversible left ventricular damage occurs. Advanced cardiac imaging and CMR derived markers of diffuse myocardial fibrosis could be utilized for this purpose. FIB-AS study is intended to invasively and non-invasively assess diffuse myocardial fibrosis in AS patients and investigate its prognostic significance in post-interventional outcomes. The results of the study will expand the current knowledge of cardiac remodeling in AS and will bring additional data on myocardial fibrosis and its clinical implications following AVR.

Barthel Index Score Predicts Mortality in Elderly Heart Failure ― A Goal of Comprehensive Cardiac Rehabilitation ―

“…Sample size calculations were performed for this observational study using the Cox proportional hazards model, as reported previously. 27 The prevalence of HF patients with a BI score <85, 1-year mortality rate, and the hazard ratio between BI score and all-cause mortality in elderly HF patients. The dotted line represents a hazard ratio (HR) of 1.0, the purple line represents HRs, and the shaded area represents 95% confidence intervals.…”

Engineering multifunctional metal/protein hybrid nanomaterials as tools for therapeutic intervention and high-sensitivity detection

“…This multifunctional molecule is validated for therapeutic intervention and for monitoring replacement myocardial fibrosis secondary to heart damage. Replacement myocardial fibrosis has prognostic value usually associated with risk factors of poor cardiac recovery, [19][20][21] that strongly affects heart function by overexpression and deposition of extracellular matrix pro-fibrotic components, mainly collagen I. However, therapies to directly target excessive fibrosis remain limited.…”

Electrocardiographic markers of adverse left ventricular remodeling and myocardial fibrosis in severe aortic stenosis

“…The study included patients with severe symptomatic AS that were scheduled for surgical AVR according to the current treatment recommendations [13]. The trial design and baseline characteristics of the patients have been described previously [23,24]. The study was approved by the local biomedical research ethics committee (number: 158200-18/9-1014-558) and conformed to the principles of the Helsinki Declaration.…”